Dr. Kelley Discusses the Rising Incidence of HCC

R. Kate Kelley, MD
Published: Tuesday, Mar 20, 2018



R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma (HCC).

Obesity is a growing problem worldwide, and having obesity and risk factors for metabolic syndrome, including diabetes and dyslipidemia, can lead to HCC. Obesity can lead to a condition called nonalcoholic fatty liver disease, which is a spectrum of diseases, such as steatohepatitis.

Just like alcoholic hepatitis, hepatitis B, and hepatitis C, steatohepatitis can lead to fibrosis, cirrhosis, and the accumulation of mutations that can eventually lead to cancer. Associated conditions with nonalcoholic fatty liver disease are now the number 1 cause of HCC in the United States, says Kelley.
SELECTED
LANGUAGE


R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the rising incidence of hepatocellular carcinoma (HCC).

Obesity is a growing problem worldwide, and having obesity and risk factors for metabolic syndrome, including diabetes and dyslipidemia, can lead to HCC. Obesity can lead to a condition called nonalcoholic fatty liver disease, which is a spectrum of diseases, such as steatohepatitis.

Just like alcoholic hepatitis, hepatitis B, and hepatitis C, steatohepatitis can lead to fibrosis, cirrhosis, and the accumulation of mutations that can eventually lead to cancer. Associated conditions with nonalcoholic fatty liver disease are now the number 1 cause of HCC in the United States, says Kelley.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x